Recursion Pharmaceuticals, Inc. (RXRX) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Scott Schoenhaus
KeyBanc Capital Markets Inc., Research Division

3

Great. Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. We’re a pleasure to have Ben Taylor, CFO of Recursion for a fireside chat.

Ben, maybe it’s helpful to sort of introduce yourself and the company for anyone that’s new to your story. And you’ve gone through a lot of changes over the last 12 to 24 months, too. So it’s worth highlighting your story to anyone that’s new to it.

Ben Taylor
CFO & President of Recursion UK

Yes, of course, happy to. So my own background, I was actually coming over from the Exscientia side of the merger. So I was the CFO and Chief Strategy Officer over at Exscientia and had been there for a little over 4 years when we brought the companies together 18 months ago. And before that, I had actually run the day-to-day operations at an oncology biotech. So got to see what it was like really digging in and setting up clinical trials, going out to the clinical trial sites, working with the FDA.

And it was actually really interesting because it was what led me into the AI-based drug discovery. What I realized is I and all of my colleagues around me and a lot of — so I’ve been in banking before that. A lot of my clients had really been guessing because the data that you have to make good decisions is so sparse. And so we’ll take data that’s coming out